Exozymes Inc.

EXOZ

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0002010788


None

No letter

4 of 13 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $6.0M
Warnings	short runway, thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	4 of 13
Graded from	filings received through Mar 30, 2026 236 days before the rescan; latest periodic filing 10-Q received Nov 13, 2026
Last close	$4.13 2026-11-06; market equity $39.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

are ubiquitous in modern life - they form the basis of medicines, fuels, plastics, food, and colors, among many other applications that together contribute to our ability to live "the good life" in the modern world. chemicals from nature via traditional extraction methods is often inefficient and often requires large amounts of biological material to extract the necessary amounts of the desired chemical compounds.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 13.9						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(28.0%)	(6.7%)	13.9	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 68.8					
Altman Z double-prime	(18.46)	0.31	73.6	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
one or more required annual facts are missing					
Current ratio	2.51x	2.68x	64.0	781	2025-12-31
Growth and financing, sleeve percentile 27.2					
Revenue growth, three-year compound	not computable	9.6%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	11.1%			
four consecutive annual FCF observations are required; found 2					
Reinvestment rate	not computable	33.9%			
NOPAT must exceed $100,000					
Asset growth, three years	not computable	3.2%			
four annual observations are required; found 2					
Net share issuance, one year	1.3%	1.6%	27.2	626	2026-03-29

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 5.3 months
Thin data	4 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(59.5%)	(1.7%)	11
Distance from 52-week high	(81.9%)	(33.0%)	9
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(24.3%)	0.6%	20
Book value to price	0.08	0.29	20
Sales to price	not computable	0.38	
Composite equity issuance, five years	not computable	13.5%	
Relative strength against the sector, log excess return	(1.08)	(0.19)	11
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$3.3M
Operating cash flow, four quarters	-$7.4M
Months of runway	5.3
Days since last periodic filing	8 (10-Q received Nov 13, 2026)
Median daily dollar volume, 63 sessions	$46,815

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$9.2M	2025-12-31	2026-03-30	10-K	26-013563
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$6.5M	2025-12-31	2026-03-30	10-K	26-013563
3	assets	us-gaap:Assets	$6.0M	2025-12-31	2026-03-30	10-K	26-013563
4	assets	us-gaap:Assets	$13.0M	2024-12-31	2026-03-30	10-K	26-013563
5	current assets	us-gaap:AssetsCurrent	$3.9M	2025-12-31	2026-03-30	10-K	26-013563
6	current liabilities	us-gaap:LiabilitiesCurrent	$1.6M	2025-12-31	2026-03-30	10-K	26-013563
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$21.1M	2025-12-31	2026-03-30	10-K	26-013563
8	operating income	us-gaap:OperatingIncomeLoss	-$9.7M	2025-12-31	2026-03-30	10-K	26-013563
9	book equity	us-gaap:StockholdersEquity	$3.4M	2025-12-31	2026-03-30	10-K	26-013563
10	liabilities	us-gaap:Liabilities	$2.6M	2025-12-31	2026-03-30	10-K	26-013563
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$169,917	2025-12-31	2026-03-30	10-K	26-013563
12	depreciation amortization	us-gaap:Depreciation	$287,961	2025-12-31	2026-03-30	10-K	26-013563
13	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$9.3M	2025-12-31	2026-03-30	10-K	26-013563
14	income tax	us-gaap:IncomeTaxExpenseBenefit	-$105,205	2025-12-31	2026-03-30	10-K	26-013563
15	current assets	us-gaap:AssetsCurrent	$10.8M	2024-12-31	2026-03-30	10-K	26-013563
16	current liabilities	us-gaap:LiabilitiesCurrent	$1.3M	2024-12-31	2026-03-30	10-K	26-013563
17	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,478,992	2026-03-29	2026-03-30	10-K	26-013563
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,367,810	2025-03-31	2025-03-31	10-K	25-001744

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.